© 2024 Boise State Public Radio
NPR in Idaho
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Apple's latest iOS (17.4) is preventing our livestreams from playing. We suggest you download the free Boise State Public Radio app & stream us there while we work to troubleshoot the issue.

CDC backs expansion of COVID boosters for all adults

Safeway pharmacist Shahrzad Khoobyari administers a Pfizer-BioNTech COVID-19 booster shot into the arm of Norman Solomon in San Rafael, Calif., in October.
Justin Sullivan
/
Getty Images
Safeway pharmacist Shahrzad Khoobyari administers a Pfizer-BioNTech COVID-19 booster shot into the arm of Norman Solomon in San Rafael, Calif., in October.

Updated November 19, 2021 at 6:15 PM ET

CDC Director Rochelle Walensky is giving the green light to COVID-19 vaccine boosters for all adults.

The announcement came just hours after a vaccine advisory committee voted unanimously to expand Moderna and Pfizer-BioNTech vaccine boosters to everyone 18 and older.

The experts met Friday afternoon following the Food and Drug Administration's decision to authorize the boosters forall adults.

The Advisory Committee on Immunization Practices voted in support of a change to COVID-19 vaccination policy that says people 50 and older should get a booster if they had a primary immunization with an mRNA vaccine (Moderna or Pfizer) at least six months before. The recommendation also applies to people 18 and older in long-term care settings.

For people at least 18 and younger than 50, the panel supported a policy that recommends they receive a booster based on their individual risks and benefits.

An analysis from a CDC working group concluded that the balance of benefits and risks for a booster is clearest for older people. The group also noted that the latest data on myocarditis, an inflammation of the heart seen rarely after vaccination but most often in young men, is "reassuring to date."

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Tags
Scott Hensley edits stories about health, biomedical research and pharmaceuticals for NPR's Science desk. During the COVID-19 pandemic, he has led the desk's reporting on the development of vaccines against the coronavirus.

You make stories like this possible.

The biggest portion of Boise State Public Radio's funding comes from readers like you who value fact-based journalism and trustworthy information.

Your donation today helps make our local reporting free for our entire community.